A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...

CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, in a deal that would bolster the buyer’s oncology ...

Kelonia shareholders will receive up to $7 billion, including $3.25 billion upfront, with additional payments tied to ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the must-buy small cap stocks to buy. On April 13, Vir Biotechnology, Inc.

Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for ...

ENA101 is designed to selectively recognize the DARKFOX‑A3 peptide presented by HLA‑A*03:01, a highly prevalent HLA allele, ...